Story perspectives

Gazvya Trial Reveals 75% Symptom Improvement in Lupus Patients

3/11/2026

Summary

Story summary

A clinical trial shows obinutuzumab (Gazvya) significantly reduces systemic lupus erythematosus symptoms, with over 75% reporting improvement after one year.
Gazvya is already approved for lupus-related kidney inflammation.
The trial found Gazvya increased remission rates and reduced the frequency of flares.
The trial showed a higher incidence of serious side effects among Gazvya patients, including pneumonia.
The Roche Group, which manufactures Gazvya, aims to expedite its worldwide availability.

1 of 1

Story summary

A clinical trial shows obinutuzumab (Gazvya) significantly reduces systemic lupus erythematosus symptoms, with over 75% reporting improvement after one year.
Gazvya is already approved for lupus-related kidney inflammation.
The trial found Gazvya increased remission rates and reduced the frequency of flares.
The trial showed a higher incidence of serious side effects among Gazvya patients, including pneumonia.
The Roche Group, which manufactures Gazvya, aims to expedite its worldwide availability.